Renaissance Capital logo

Orchard Therapeutics Priced, Nasdaq: ORTX

Developing stem cell gene therapies for rare diseases.

Industry: Health Care

First Day Return: 0.0%

We are a commercial-stage, fully-integrated biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Our gene therapy approach seeks to transform a patient’s own, or autologous hematopoietic stem cells (HSCs) into a gene-modified drug product to treat the patient’s disease through a single administration. We achieve this outcome by utilizing a lentiviral vector to introduce a functional copy of a missing or faulty gene into the patient’s autologous HSCs through an ex vivo process, resulting in a drug product that can then be re-introduced into the patient at the bedside. Our portfolio currently includes Strimvelis, our commercial-stage gammaretroviral-based product for the treatment of ADA-SCID, five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. We expect to submit a BLA with the FDA for our product candidate OTL-101, a lentiviral gene therapy for ADA-SCID, in 2020, followed by an MAA with the EMA. We also plan to submit an MAA with the EMA for our next most advanced clinical candidate, OTL-200 for the treatment of MLD, in 2020 followed by a BLA with the FDA.

Orchard Therapeutics (ORTX) Performance

Created with Highcharts 10.3.2Chart context menuORTX vs. IPO Index (IPOUSA)Jan 2019May 2019Sep 2019Jan 2020May 2020Sep 2020Jan 2021May 2021Sep 2021Jan 2022May 2022Sep 2022Jan 2023May 2023Sep 2023Jan 2024May 2024Sep 2024Jan 2025May 20250%+ 100%+ 200%-100%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index